Technology transfer

GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia

Retrieved on: 
Friday, June 2, 2023

1st that it has successfully obtained final approval from the Indonesian Ministry of Health for the construction of a plasma fractionation plant and technology transfer.

Key Points: 
  • 1st that it has successfully obtained final approval from the Indonesian Ministry of Health for the construction of a plasma fractionation plant and technology transfer.
  • Earlier in Jan., the company was successfully selected by the Indonesian government as the preferred bidder for the license of plasma fractionation plant construction and technology transfer business.
  • GC Biopharma is the only company worldwide that has successfully completed the turnkey project of a plasma fractionation plant in an overseas market.
  • Since its first export of a plasma fractionation plant to Thailand, GC Biopharma has been accumulating expertise and know-how in overseas plant construction through successful projects in various countries including China and Canada.

eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces the signature of a put option for the potential acquisition of Skyepharma to build a new European bio-CDMO leader

Retrieved on: 
Tuesday, May 30, 2023

58.1% of the share capital (on a fully-diluted basis) of Oleron Pharma which holds 100% of the share capital of Skyepharma.

Key Points: 
  • 58.1% of the share capital (on a fully-diluted basis) of Oleron Pharma which holds 100% of the share capital of Skyepharma.
  • The proposed transaction would constitute the “Initial Business Combination” (or “IBC”), described in the IPO Prospectus of eureKING.
  • After completion of both the Acquisition and the Contribution, Oleron Pharma, and thus Skyepharma, will be fully owned by eureKING.
  • Skyepharma was created in 1996 and it acquired its current industrial site, in Saint-Quentin-Fallavier, near Lyon in 1997.

Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator

Retrieved on: 
Tuesday, May 23, 2023

SAN DIEGO and GAINESVILLE, Ga., May 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: SCTL ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been selected by Atossa Therapeutics (Nasdaq: ATOS ) to provide a range of its Clinical Trial Services (CTS) offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen.

Key Points: 
  • SAN DIEGO and GAINESVILLE, Ga., May 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: SCTL ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been selected by Atossa Therapeutics (Nasdaq: ATOS ) to provide a range of its Clinical Trial Services (CTS) offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen.
  • The agreement spans a range of activities including analytical method transfer/development and validation, cleaning verification method validation, manufacturing of multiple R&D engineering batches, and stability testing of the R&D engineering batches.
  • “Societal’s demonstrated expertise in the technology transfer of established drug products, along with our long track record of successfully formulating and manufacturing innovative small molecules, positions us well to align with Atossa and support the ongoing clinical development of the company’s proprietary oral formulation of (Z)-endoxifen.
  • We are eager to initiate this important work and deliver exceptional results for Atossa,” said David Enloe, chief executive officer of Societal CDMO.

Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

Retrieved on: 
Wednesday, May 24, 2023

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

Key Points: 
  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
  • APT also has the first right to evaluate additional phages discovered by IPTC researchers for inclusion in APT’s phage bank.
  • “We are thrilled to enter into this collaboration and license agreement and to continue our work with Dr. Nir-Paz, Dr. Hazan, and the impressive group of phage scientists at Hebrew University and Hadassah Medical Center.
  • I am thrilled to see the Israeli Phage Therapy Center entering into a collaboration and licensing agreement with Adaptive Phage Therapeutics, the leading phage therapy biotech firm,” said Ran Nir-Paz, MD, Professor of Clinical Microbiology and Medicine at the department of Clinical Microbiology and Infectious Diseases at the Hadassah Hebrew University Medical Center and co-founder of the Israeli Phage Therapy Center.

Lightwave Logic Begins Commercialization of its Electro-optic Polymer Materials

Retrieved on: 
Thursday, May 25, 2023

ENGLEWOOD, Colo., May 25, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced the company's first commercial material supply license agreement for its Perkinamine® chromophore materials.

Key Points: 
  • ENGLEWOOD, Colo., May 25, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced the company's first commercial material supply license agreement for its Perkinamine® chromophore materials.
  • This initial commercial material supply license agreement will provide Perkinamine® chromophore materials for polymer based photonic devices and photonic integrated circuits (PICs).
  • Supplying licensed materials is one prong of the Company's three-prong revenue model and business strategy that includes polymer modulator products as well as technology transfer.
  • The supply license agreement terms include supply of electro-optic polymer material, license initiation fee, per unit royalties, minimum royalty levels that increase annually, and minimum sales volume in units.

Africa-China dialogue provides boost to green industrial revolution

Retrieved on: 
Wednesday, May 24, 2023

There was a specific focus on the potential for investment, and knowledge and technology transfer between Africa and China.

Key Points: 
  • There was a specific focus on the potential for investment, and knowledge and technology transfer between Africa and China.
  • Both are partners in the Africa Renewable Energy Manufacturing Initiative, along with the African Climate Foundation, Bloomberg Philanthropies, and ClimateWorks Foundation.
  • ClimateWorks Foundation is proud to support this South-South cooperation, and we hope to foster greater dialogue and partnerships among institutions and experts to help scale global green recovery and sustainable development."
  • With a sharp focus on facilitating South-South cooperation, the Africa Renewable Energy Manufacturing Initiative is planning additional roundtables to be held throughout the coming year as it continues to drive investment and mobilize action for Africa's green industrial development.

Africa-China dialogue provides boost to green industrial revolution

Retrieved on: 
Wednesday, May 24, 2023

There was a specific focus on the potential for investment, and knowledge and technology transfer between Africa and China.

Key Points: 
  • There was a specific focus on the potential for investment, and knowledge and technology transfer between Africa and China.
  • Both are partners in the Africa Renewable Energy Manufacturing Initiative, along with the African Climate Foundation, Bloomberg Philanthropies, and ClimateWorks Foundation.
  • ClimateWorks Foundation is proud to support this South-South cooperation, and we hope to foster greater dialogue and partnerships among institutions and experts to help scale global green recovery and sustainable development."
  • With a sharp focus on facilitating South-South cooperation, the Africa Renewable Energy Manufacturing Initiative is planning additional roundtables to be held throughout the coming year as it continues to drive investment and mobilize action for Africa's green industrial development.

Universal Display Corporation and PPG Celebrate Opening of State-of-the-Art OLED Manufacturing Site in Shannon, Ireland

Retrieved on: 
Thursday, May 18, 2023

Universal Display Corporation (Nasdaq: OLED) (UDC) and PPG (NYSE: PPG) today officially opened a new state-of-the-art organic light-emitting diode (OLED) manufacturing facility in Shannon, Ireland.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED) (UDC) and PPG (NYSE: PPG) today officially opened a new state-of-the-art organic light-emitting diode (OLED) manufacturing facility in Shannon, Ireland.
  • View the full release here: https://www.businesswire.com/news/home/20230517005788/en/
    Universal Display Corporation and PPG's new state-of-the-art OLED manufacturing site in Shannon, Ireland.
  • Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation.
  • Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

Retrieved on: 
Tuesday, May 16, 2023

For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.

Key Points: 
  • For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
    tiakis Biotech AG and Northway Biotech collaboration - tiakis Biotech AG and Northway Biotech:
    "The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
  • The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
  • Andre Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities.
  • By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields.

EQS-News: SFC Energy AG achieves record results in first quarter of 2023

Retrieved on: 
Tuesday, May 16, 2023

Dr. Peter Podesser, CEO of SFC Energy AG: “We are pleased that we just recorded the best first quarter in our company’s history.

Key Points: 
  • Dr. Peter Podesser, CEO of SFC Energy AG: “We are pleased that we just recorded the best first quarter in our company’s history.
  • We are continuing on this path, which we are the only company in the industry to pursue to date.
  • In the period from January 1 to March 31, 2023, the SFC Energy Group generated significant growth in sales of 53.3% to EUR 27,454 thousand (Q1/2022: EUR 17,905 thousand).
  • This positive development resulted from strong organic growth in both the Clean Energy segment and the Clean Power Management segment.